19. Male breast cancer: Aetiology, genetics and clinical management

International Journal of Clinical Practice

Volumn 56, Issue 10, 2002, Pages 750-754

  Tischkowitz, M D ^a   Hodgson, S V ^a   Fentiman, I S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN;

ARTICLE; BODY WEIGHT DISORDER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; GENE MUTATION; HOT FLUSH; HUMAN; INCIDENCE; LIBIDO DISORDER; MALE; MALE BREAST; MAMMOGRAPHY; MASTOIDECTOMY; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; UGANDA; ZAMBIA;

BREAST NEOPLASMS, MALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; PENETRANCE; PROGNOSIS; RISK FACTORS;

EID: 0036957749     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sasco AJ, Lowenfels AB, Pasker-de Jong J. Epidemiology of male breast cancer: a meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993; 53: 538-549.
2. Ojara EA. Carcinoma of the male breast in Mulago Hospital, Kampala. East Afr Med J 1978; 55(10): 489-491.
3. Bhagwandin S. Carcinoma of the male breast in Zambia. East Afr Med J 1972; 49: 176-179.
4. Steinitz R, Katz L, Ben-Hur M. Male breast cancer in Israel: selected epidemiologic aspects. J Med Sci 1981; 17: 816-821.
5. Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst 1985; 74: 371-375.
6. Lenfant-Pejovic M-H, Mlika-Cabanne N, Bouchardy C et al. Risk factors for male breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990; 45: 661-665.
7. Tynes T, Andersen A. Electromagnetic fields and male breast cancer. Lancet 1990 336: 1596.
8. Loomis DP. Cancer of breast among men in electrical occupations. Lancet 1992; 339: 1482-1483.
9. McClure JA, Higgins CC. Bilateral carcinoma of male breast after estrogen therapy. JAMA 1951; 146: 7-9.
10. Symmers WSC. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. BMJ 1968; 2: 83-85.
11. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Gen 1971; 8: 460-461.
12. Thomas DB, Jimenez LM, McTiernan A et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 1992; 135: 734-748.
13. Ribeiro GG, Phillips HU, Skinner LG. Serum oestradiol-17β, testosterone, luteinising hormone and follicle-stimulating hormone in males with breast cancer. Br J Cancer 1980; 41: 474-477.
14. Casagrande JT, Hanisch R, Pike MC et al. A case-control study of male breast cancer. Cancer Res 1988; 48: 1326-1330.
15. Olsson H, Ranstam J. Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. J Natl Cancer Inst 1988; 80: 679-683.
16. Schottenfeld D, Lilienfeld AM, Diamond H. Some observations on the epidemiology of breast cancer among males. Am J Public Health 1963; 5: 890-897.
17. Carlsson G, Hafstrom L, Jonsson P. Male breast cancer. Clin Oncol 1981; 7: 149-155.
18. Andersen JA, Gram JB. Male breast at autopsy. Acta Pathol Microbiol Immunol Scand 1982; 90(3): 191-197.
19. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000; 92(14): 1126-1135.
20. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60(2): 313-319.
21. Basham VM, Lipscombe JM, Ward JM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002; 4: R2.
22. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480-1490.
23. De Jong MM, Nolte IM, te Meerman GJ et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002; 39: 225-242.
24. Fackenthal, JD, Marsh DJ, Richardson AL et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38: 159-164.
25. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
26. Scheike O. Male breast cancer. Acta Pathol Microbiol Scand 1975; Suppl 251: 1-33.
27. Ribeiro GG, Swindell R, Harris M et al. A review of management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 1996; 5: 141-146.
28. Treves N, Holleb AJ. Cancer of the male breast: a report of 146 cases. Cancer 1955; 8: 1239-1250.
29. Goss PE, Reid C, Pintilie M et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85: 629-639.
30. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multi-institutional survey. Cancer 1998; 83: 498-509.
31. Cutuli B, Lacroze M, Dilhuydy JM et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995; 31A: 1960-1964.
32. Stierer M, Rosen H, Weitensfelder W et al. Male breast cancer: Austrian experience. World J Surg 1995; 19: 687-693.
33. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992; 65: 252-254.
34. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987; 10: 55-60.
35. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989; 64: 1583-1585.
36. Neifeld JP, Meyskens FL, Tormey DC, Javadpour N. The role of orchiectomy in the management of advanced male breast cancer. Cancer 1976; 37: 992-995.
37. Labrie F, Dupont A, Belanger A et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 1990; 13: 275-278.
38. Doberauer CN, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988; 62: 474-478.
39. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002; 25(3): 235-237.
40. Borgen, PI, Wong GY, Vlamis V et al. Current management of male breast cancer: a review of 104 cases. Ann Surg 1992; 215: 451-459.
41. Willsher PC, Leach IH, Ellis IO et al. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997; 173: 185-188.
42. Guinee VF, Olsson H, Moller T et al. The prognosis of breast cancer in males: a report of 335 cases. Cancer 1993; 71: 154-161.